The paroxetine 352 bipolar trial: A study in medical ghostwriting

International Journal of Risk and Safety in Medicine

Volumn 24, Issue 4, 2012, Pages 221-231

  Amsterdam, Jay D ^a   McHenry, Leemon B ^b  

^a The Science Center Philadelphia   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bipolar; depression; Ghostwriting; industry sponsorship; key opinion leaders; litigation; paroxetine; SSRI

Indexed keywords

IMIPRAMINE; LITHIUM CARBONATE; PAROXETINE; PLACEBO;

AGGRESSION; ARTICLE; ASTHENIA; BACKACHE; BIPOLAR DEPRESSION; CONSTIPATION; CONTROLLED STUDY; DELUSION; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; DYSPEPSIA; GHOSTWRITING; HALLUCINATION; HEADACHE; HOMICIDAL IDEATION; HUMAN; INFECTION; INSOMNIA; LAW SUIT; MAJOR CLINICAL STUDY; MANIA; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARANOIA; POST HOC ANALYSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCIENTIFIC MISCONDUCT; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIPOLAR DISORDER; CONFLICT OF INTEREST; DOUBLE-BLIND METHOD; HUMANS; IMIPRAMINE; PAROXETINE; SCIENTIFIC MISCONDUCT; TREATMENT OUTCOME;

EID: 84872238947     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2012-0571     Document Type: Article

References (31)

1. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2(5):e138.
2. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007;297(3):308-31.
3. Lenzer J. What can we learn from medical whistleblowers? PLoS Med. 2005;2(7):e209.
4. Complaint of Scientific Misconduct against Dwight Evans, Laszlo Gyulai, Charles Nemeroff, Gary S. Sachs and Charles Bowden, http://psychrights.org/ Research/Digest/Science4Sale/110708EthicsComplaintAgainstEvansGyualai NemeroffSachsBowdenetal.pdf (Accessed May 2012).
5. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906-12.
6. http://abcnews.go.com/images/Primetime/paxil bpg.pdf (Accessed May 2012).
7. Nemeroff CB, editor. Advancing the treatment of mood and anxiety disorders: The first 10 years' experience with paroxetine. Psychopharm Bul. 2003;37/1.
8. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapidcycling affective disorder: Contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145(2):179-84.
9. Sachs GS, Lafer B, Stoll AL, Banov M, Tibault AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55:391-3.
10. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, NolenWA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232-9.
11. Dunner DL. Sub-types of bipolar affective disorder with particular regard to bipolar II. Psychiat Developments. 1983;1:75- 85
12. Goodwin FK, Jamison KR. Manic-Depressive Illness. Bipolar Disorders and Recurrent Depression. 2nd ed. New York: Oxford University Press; 2007.
13. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150:720-7.
14. http://www.gsk-clinicalstudyregister.com/result detail.jsp?protocolId= 29060%2F352&studyId=F1D83A94-2628-4C9C- 83A5-11D00A2D30AC&compound= paroxetine) (Accessed April 2012).
15. http://dida.library.ucsf.edu/ (Accessed May 2012).
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
17. Guy W, editor. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338, Washington, DC: US Department of Health, Education, and Welfare; 1976. pp. 218-22.
18. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity, and sensitivity. Brit J Psychiatry. 1978;133:429-35.
19. US Code of Federal Regulations, Consolidated Good Clinical Practice (GCP) Guidelines, US DHHS, Food & Drug Administration Center for Drug Evaluation and Research (CDER), Washington, DC; April 1, 2002.
20. American Psychiatric Association: Practice guidelines for 1994;151(Suppl):1-36.
21. American Psychiatric Association Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(Suppl):1-50.
22. http://blogs.nature.com/news/files/2012/06/Jay-Amsterdam-today-filed-a- 24-page-complaint-with-the-Office-of- Research-Integrity-at-the-US-National- Institutes-of-Health.pdf (Accessed August 2012).
23. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. JAMA. 2008;299/15:1833-5.
24. http://www.icmje.org. (Accessed June 2012).
25. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762-72.
26. McHenry L, Jureidini J. Industry-sponsored ghostwriting in clinical trial reporting:Acase study, Account Res. 2008;15:152- 67.
27. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Ann Inter Med. 2006;145:284-93.
28. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA. 2008;299/15:1800-12.
29. Jureidini J, McHenry L, Mansfield P. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med. 2008;20(1-2):73-81.
30. Fugh-Berman AJ. The haunting of medical journals: How ghostwriting sold "HRT". PLoS Med. 2010;7(9):e1000335. doi:10.1371/journal.pmed.1000335.
31. Newman M. The rules of retraction. BMJ. 2010;341:1246-8.